Ziprasidone
Geodon, Ziprasidone (ziprasidone) is a small molecule pharmaceutical. Ziprasidone was first approved as Geodon on 2001-02-05. It is used to treat schizophrenia, schizophrenia spectrum and other psychotic disorders, and tourette syndrome in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 2A, and D(2) dopamine receptor. In addition, it is known to target sodium-dependent serotonin transporter, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 1D, 5-hydroxytryptamine receptor 1A, histamine H1 receptor, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 7, and sodium-dependent noradrenaline transporter.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Geodon, Ziprasidone (discontinued: Geodon, Ziprasidone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| geodon | New Drug Application | 2022-02-23 |
| ziprasidone | ANDA | 2025-01-06 |
| ziprasidone hydrochloride | ANDA | 2024-12-23 |
| ziprasidone mesylate | ANDA | 2024-08-07 |
| ziprasidone ziprasidone | ANDA | 2023-08-07 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ZIPRASIDONE HYDROCHLORIDE, GEODON, VIATRIS | |||
| 2025-01-28 | M-232 | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J3486 | Injection, ziprasidone mesylate, 10 mg |
Clinical
Clinical Trials
159 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 4 | 8 | 20 | 35 | 23 | 88 |
| Psychotic disorders | D011618 | — | F20.81 | — | 4 | 10 | 24 | 9 | 45 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 2 | 15 | 14 | 9 | 40 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | 3 | 4 | 9 | 2 | 17 |
| Depression | D003863 | — | F33.9 | — | 3 | 4 | 5 | 2 | 14 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 3 | 2 | 4 | 1 | 10 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 1 | 3 | 3 | 7 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 2 | 1 | 3 | 1 | 7 |
| Psychomotor agitation | D011595 | — | — | — | — | 1 | 2 | 3 | 6 |
| Weight gain | D015430 | HP_0004324 | — | 1 | 1 | — | 3 | — | 5 |
Show 22 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 2 | 1 | — | — | 3 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | 1 | — | 1 | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | 1 | — | — | 1 |
| Anger | D000786 | — | — | — | — | 1 | — | — | 1 |
| Apathy | D057565 | HP_0000741 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autistic disorder | D001321 | HP_0000717 | F84.0 | — | 1 | — | — | 1 | 2 |
| Cognition disorders | D003072 | — | — | — | 2 | — | — | — | 2 |
| Anhedonia | D059445 | — | R45.84 | — | 1 | — | — | — | 1 |
| Social phobia | D000072861 | EFO_1001917 | F40.1 | — | 1 | — | — | — | 1 |
| Conduct disorder | D019955 | EFO_0004216 | F91 | — | 1 | — | — | — | 1 |
| Attention deficit and disruptive behavior disorders | D019958 | HP_0010865 | F91.3 | — | 1 | — | — | — | 1 |
| Problem behavior | D000066553 | — | — | — | 1 | — | — | — | 1 |
| Oppositional defiant disorder | D000096865 | — | — | — | 1 | — | — | — | 1 |
| Borderline personality disorder | D001883 | HP_0012076 | F60.3 | — | 1 | — | — | — | 1 |
| Personality disorders | D010554 | HP_0012075 | F60.6 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
| Body weight | D001835 | EFO_0004338 | — | 1 | — | — | — | — | 1 |
| Addictive behavior | D016739 | EFO_0004347 | — | 1 | — | — | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | — | — | — | — | 1 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | — | — | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 3 | 3 |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | — | — | 2 | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Emergencies | D004630 | — | — | — | — | — | — | 1 | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 1 | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 1 | 1 |
Show 55 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ziprasidone |
| INN | ziprasidone |
| Description | Ziprasidone is a piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms. It has a role as a psychotropic drug, a histamine antagonist, a muscarinic antagonist, a serotonergic antagonist, a dopaminergic antagonist and an antipsychotic agent. It is a member of piperazines, an organochlorine compound, a member of indolones and a 1,2-benzisothiazole. |
| Classification | Small molecule |
| Drug class | antipsychotic with binding activity on sertonin (5-HT2A) and dopamine (D2) receptors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1 |
Identifiers
| PDB | — |
| CAS-ID | 146939-27-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL708 |
| ChEBI ID | 10119 |
| PubChem CID | 60854 |
| DrugBank | DB00246 |
| UNII ID | 6UKA5VEJ6X (ChemIDplus, GSRS) |
Target
Agency Approved
HTR2C
HTR2C
HTR2A
HTR2A
DRD2
DRD2
Organism
Homo sapiens
Gene name
HTR2C
Gene synonyms
HTR1C
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2C
Protein synonyms
5-HT-1C, 5-HT1C, 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled, 5-hydroxytryptamine receptor 1C, serotonin 5-HT-1C receptor, serotonin 5-HT-2C receptor, Serotonin receptor 2C
Uniprot ID
Mouse ortholog
Htr2c (15560)
5-hydroxytryptamine receptor 2C (Q5WRU6)
Alternate
SLC6A4
SLC6A4
HTR1B
HTR1B
HTR1D
HTR1D
HTR1A
HTR1A
HRH1
HRH1
HTR1E
HTR1E
HTR7
HTR7
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A4
Gene synonyms
HTT, SERT
NCBI Gene ID
Protein name
sodium-dependent serotonin transporter
Protein synonyms
5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4
Uniprot ID
Mouse ortholog
Slc6a4 (15567)
sodium-dependent serotonin transporter (Q60857)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Geodon – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Ziprasidone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,103 documents
View more details
Safety
Black-box Warning
Black-box warning for: Geodon, Ziprasidone, Ziprasidone hydrochloride, Ziprasidone mesylate, Ziprasidone ziprasidone
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,346 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use